MAPT and Alzheimer disease: Accordingly, the most clinically useful biomarkers identified to date are CSF levels of Aβ1–42, total Tau protein, and phospho-Tau-181, which are significantly elevated in AD [186, 187], but are unable to differentiate other forms of dementia.